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Anaphylaxis in an emergency care setting:
a one year prospective study in children
and adults
Athamaica Ruiz Oropeza1*, Annmarie Lassen2, Susanne Halken3, Carsten Bindslev-Jensen1 and Charlotte G Mortz1
Abstract
Background: Current data on anaphylaxis is based on retrospective and register based studies. The objective of
this study was to describe the epidemiology of anaphylaxis in a 1 year prospective study at the emergency care
setting, Odense University Hospital, Denmark (2013–2014).
Methods: Prospective study at the emergency care setting, Odense University Hospital, Denmark (2013–2014). To
identify anaphylaxis cases, records from all patients with clinical suspicion on anaphylaxis or a related diagnosis
according to the International Classification of Diseases 10 and from patients treated at the emergency care setting
or at prehospital level with adrenaline, antihistamines or glucocorticoids were reviewed daily. The identified cases
were referred to the Allergy Center, where a standardized interview regarding the anaphylactic reaction was
conducted. International guidelines were applied for the assessment of anaphylaxis and its pharmacological
treatment. Severity of the anaphylactic reaction was evaluated according to Sampson’s severity score.
Results: We identified 180 anaphylactic patients. Anaphylaxis represented 0.3%–0.4% of all contacts in the
emergency care setting with an incidence rate of 26.8 cases per 100,000 person years (95% CI: 14.3–45.8) in children
and 40.4 cases per 100,000 person years (95% CI: 32.8–49.3) in adults. Moderate to severe anaphylaxis was
registered in 96% of the cases. Skin (96%) and respiratory (79%) symptoms were the most frequent registered, but
7% of cases in adults occurred without skin manifestations. The most common elicitor in children was food (61%),
while drugs (48%) and venom (24%) were the main suspected elicitors in adults. Adrenaline was administered in
25% of the cases and it was significantly less administered than glucocorticoids (83%) and antihistamines (91%). The
mortality rate during our study period was 0.3 cases per 100,000 person years.
Discussion: This is one of the first prospective studies on the epidemiology of anaphylaxis in children and adults,
where the patients are identified not only based on diagnosis codes but also on history, symptoms and treatment
and thereafter classified according to international diagnosis criteria for anaphylaxis.
A limitation of this study is that only patients who gave consent to participate in the study were included.
Furthermore, patients may have attended other hospitals during the study period. Therefore, the estimates are
minimum figures.
Conclusion: The prospective study design with a broad search profile yield a higher incidence than previously
reported. Adrenaline was administered in a low proportion of the patients with moderate to severe anaphylaxis.
Standardized diagnosis criteria among physicians treating anaphylaxis are needed.
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Background
Anaphylaxis is a severe, life-threatening generalized
hypersensitivity reaction [1]. The lifetime prevalence of
anaphylaxis in the general population is estimated to be
about 0.05–2.0% [2] with a variable Incidence Rate (IR)
from 1.5 to 7.9 cases per 100,000 person years in Europe
[3] to 42 cases per 100,000 person years in the United
States [4]. In the emergency department (ED), anaphylaxis
has been reported in 0.04–0.96% of all contacts [5–7].
Overall, the case fatality is reported below 0.0001% [3].
The most severe cases of anaphylaxis are usually related
to symptoms from the cardiovascular and respiratory
systems [8]. Food has been reported as the most common
elicitor in children, while drugs and venom are more
frequent in adults [2, 3, 9]). Nevertheless, the diagnosis of
anaphylaxis may be difficult in patients with many symp-
toms, without a certain history of allergy and in the absence
of symptoms from the skin and mucosal tissue [1, 10, 11].
Moreover, the elicitors may vary according to age, sex and
geographical area [1, 3]. First line treatment of anaphylaxis
is adrenaline [1, 12], but previous studies have reported that
only a low proportion of anaphylaxis patients receive this
treatment [6, 9, 13, 14].
The acute onset of anaphylaxis, the variable symptoms
and its transient and unpredictable nature may compli-
cate prospective studies. As a consequence most of the
current knowledge on anaphylaxis is derived from retro-
spective or register based studies [1–4, 6–12]. To our
knowledge, only few studies have assessed anaphylaxis
prospectively [5, 13, 15]. A retrospective or register
based study is likely to underestimate anaphylaxis due to
misclassification in diagnosis code, unclear patient his-
tory in the ED or the symptoms may have resolved
spontaneously, when the patient arrives in the ED or by
prehospital treatment. Thus, there is still a lack of evi-
dence as regards the incidence, severity and epidemio-
logical characteristics of anaphylactic reactions.
The aim of this prospective study was to evaluate pa-
tients with symptoms, diagnosis and treatment suggest-
ive of anaphylaxis at admission to the emergency care
setting. Our primary objective was to estimate the period
prevalence and the Incidence Rate (IR) of anaphylaxis
during 2013–2014 in children and adults admitted to
the emergency care setting of Odense University Hospital.
The secondary objective was to describe the severity of
the anaphylactic reaction, symptoms, suspected elicitors
and the pharmacological treatment administered.
Methods
We conducted a prospective, non-interventional study
in all patients seen at the ED and the Acute Pediatric
Ward (APW), Odense University Hospital (OUH),
Denmark, during 1st May 2013–30th April 2014.
OUH is a 1000-bed teaching hospital representing all
specialties. The population served by the ED and APW
consists of four well-defined municipalities with a mixed
rural-urban population of 288,587 persons (adults n =
240,070; children n = 48,517), representative for the gen-
eral population. The ED attends patients ≥ 15 years of
age and the APW children (0–14 years old), with a 24-h
acute medical care.
In the prehospital setting, the response to an acute request
of prehospital assistance is a two-tiered system, in which an
ordinary ambulance manned with two emergency medical
technicians (EMTs) is supplied by the Mobile Emergency
Care Unit (MECU). The MECU consists of a rapid re-
sponse car manned with a specialist in Anesthesiology
and an EMT [16]. The ambulance can be called directly
or the patients can attend either their general practi-
tioners or a doctor on call, and then be referred to the
emergency care setting in relevant cases.
Data on the population living in the hospitals catch-
ment area during our study period were collected at the
StatBank Denmark website (http://www.statistikban-
ken.dk; accessed August 2016).
Participants
The cases were eligible when presenting to the ED or
APW with any clinical suspicion on anaphylaxis or a diag-
nosis related to anaphylaxis according to the International
Classification of Diseases 10 (ICD-10), and/or when
treated at the ED or the APW or at prehospital level with
adrenaline, antihistamines or glucocorticoids (Fig. 1).
The eligible cases in the ED were identified by daily
electronic screening of the inclusion criteria among all
records in the ED. All the matched records were
reviewed to recognize the possible anaphylaxis cases. To
identify the eligible cases from the APW, all records for
the admitted patients during the study period were
reviewed, and diagnose codes for children observed during
admission for less than 24 h were reviewed. Furthermore,
all medical doctors in the ED and APW were informed to
refer all patients with suspicion of anaphylaxis.
The identified cases were referred to the Allergy Cen-
ter (AC) and assessed according to the World Allergy
Organization (WAO) [1] and the European Academy of
Allergy and Clinical Immunology (EAACI) [12] clinical
criteria for the diagnosis of anaphylaxis (Fig. 1). These
criteria state that anaphylaxis is highly likely when any
of the following 3 criteria is fulfilled: 1) sudden skin and/
or mucosal tissue symptoms together with respiratory
compromise and/or severe hypotension (systolic pres-
sure under 90 mmHg for adults and age-specific for
children) and/or end-organ dysfunction, 2) symptoms
from two or more organ systems (skin and/or mucosal
tissue, respiratory, cardiovascular and/or gastrointestinal
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systems) suddenly after exposure to a likely allergen, or
3) severe hypotension after exposure to a known allergen
for that patient. Only patients fulfilling WAO/EAACI
clinical criteria for the diagnosis of anaphylaxis were
included.
Patients with physical or mental incapacity of giving
consent, without a Danish personal identification num-
ber and/or residing outside the hospitals catchment area
at the time of contact were excluded, as well as inpa-
tients developing anaphylaxis (Fig. 1). If a patient had
multiple contacts with anaphylaxis at the ED or the
APW over the study period, data from the first contact
was used.
Data collection
During the first visit at the AC a standardized interview
regarding symptoms, suspected elicitors and
administered treatment in relation to the anaphylactic
reaction was conducted. The history, objective findings
including vital parameters, and the administered
pharmacological treatment in the ED, APW and at pre-
hospital level were drawn and complemented from the
patient files. Data were entered in duplicate in an Epi-
Data® database.
Outcomes
The period prevalence of anaphylaxis cases at the ED
and APW was calculated as the number of included
children and adolescents/adults per total number of
contacts in the APW and the ED, respectively. The
period prevalence in the population was calculated as
the number of patients having anaphylaxis per the total
numbers of habitants in the hospital’s catchments area
during the study period. Finally, the IR of anaphylaxis
Fig. 1 Flowchart of patients with suspected anaphylaxis seen in the Emergency Department (ED) and Acute Pediatric Ward (APW) from May 2013
to April 2014
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was calculated as the number of patients having
anaphylaxis for the first time per 100,000 person years.
Although adolescents (15–17 years) were attended in
the ED at OUH, the variable age group was defined as
children/adolescents (0–17 years) and adults (>18 years).
Age was given as median and 25–75 percentiles (IQR).
The severity of the anaphylactic reaction was gradu-
ated according to Sampson’s severity score [17], the
severity score that is used routinely in our AC [18]. It
consists of five severity grades; from grade 1, mild symp-
toms, to grade 5 severe symptoms. The severity grade
depends on symptoms from the organ system that is
mostly affected. In this scoring system is possible to
graduate the reaction also if only single symptoms,
such as hypotension, are registered, and it refers to
key symptoms that are absolute indications for adren-
aline administration. Moderate to severe anaphylaxis
was defined as grade 3–5.
The pharmacological treatment administered was assessed
in relation to EAACI guidelines recommendations [12].
First-line: adrenaline intramuscular (IM) or intravenous
(IV). Third-line: antihistamines and glucocorticoids. Inhaled
adrenaline was also assessed. Additionally, we evaluated the
administration of adrenaline according to recommendations
in Sampson’s severity score and the prescription of adren-
aline auto injector at the discharge point.
Statistical analysis
Statistical analysis was performed with Stata IC 14.0
(Stata Corporation LP®, College Station, Texas, USA).
Comparisons were made by χ2-based table analysis. Stat-
istical significance was defined as p < 0.05. Both the IR
and the period prevalence were calculated with the
correspondent 95% confidence interval based on a Pois-
son distribution (CI 95%).
Ethics
The study was approved by the Data Protection Agency
(J. no. 12/26172) and the Regional Committees on
Health Research Ethics for Southern Denmark (J. no. S-
20120203). The patients were included after informed
consent.
Results
Numbers of individuals at each stage of the study and
reasons for exclusion are presented in Fig. 1. Of these,
180 (female 55%, male 45%) fulfilled the criteria for the
diagnosis of anaphylaxis and were included in the study;
157 (87%) adults with a median age of 45 years (IQR,
31.5–60.5) and 23 (13%) children/adolescents with a
median age of 9 years (IQR, 2–15).
The proportion of individual patients with anaphylaxis
in the APW was calculated to 0.4% (95% CI: 0.2–0.7) of
all contacts and in the ED to 0.3% (95% CI: 0.2–0.3) of
all contacts. The period prevalence of anaphylaxis in
OUH’s catchments area was estimated to 0.04% (95% CI:
0.03–0.07) in children and 0.06% (95% CI: 0.05–0.07) in
adults. Fifteen patients (children n = 3, adults n = 12)
were seen more than once during the study period
representing eighteen extra contacts in the emergency
care setting.
Among the 180 patients included in the study, 110
(children n = 13, adults n = 97) experienced anaphylaxis
for the first time giving an IR of 26.8 cases per 100,000
person years (95% CI: 14.3–45.8) in children and 40.4
cases per 100,000 person years (95% CI: 32.8–49.3) in
adults.
One fatality due to anaphylaxis was registered during
the study period. This fatal case represented 0.5% of our
study population and a mortality rate of 0.3 cases per
100,000 person years in our study period. Since the
patient died before arriving to the ED we chose to de-
scribe the findings independently and therefore this case
is not included in further analysis.
Severity of the anaphylactic reaction and symptoms
None of those fulfilling the WAO/EAACI criteria for
anaphylaxis had mild anaphylaxis according to Samp-
son’s severity score (grade 1). Only 7 cases had grade 2
anaphylaxis, while 173 (96%) had moderate to severe
anaphylaxis (grade 3–5) (Fig. 2). There was no statistical
difference in the severity of anaphylaxis among children/
adolescents compared to adults.
Skin manifestations and respiratory symptoms were
the most frequent registered symptoms (Table 1). A total
of 169 patients (94%) had skin symptoms and 143 (79%)
had respiratory symptoms. There was no statistical
difference in the distribution of the symptoms from the
different organ systems when comparing children/ado-
lescents with adults neither when including all patients
with anaphylaxis nor in the group with moderate to se-
vere anaphylaxis. However, in the group of patients with
Fig. 2 Severity grades of anaphylaxis (Sampson’s severity score) in
children/adolescents and adults fulfilling the WAO/EAACI criteria for
the diagnosis of anaphylaxis (n = 180)
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grade 4–5 anaphylaxis, cardiovascular symptoms were
more often reported in adults than in children/adolescents
(p = 0.056) with tachycardia and severe hypotension as
main symptoms.
Elicitor profile
Drugs (44%), food products (22%) and venom (21%) were
the most frequent reported elicitors in our study group.
The elicitor profile varied according to the age groups;
food products were more often reported in children/
adolescents compared to adults (p < 0.001), while drugs
(p = 0.019) and venom (p = 0.035) were more often regis-
tered in adults compared to children. In 12% of all cases
the elicitors were unknown. Inhalation allergens (cat) were
reported in only 1% of the patients (Table 2).
Treatment
Independently of the severity of the reaction, glucocorti-
coids and antihistamines were more often administrated
than adrenaline.
Of the 180 patients included 37% (n = 66) received
medical attention at prehospital level (General Practi-
tioner n = 6, Doctor on call n = 7, MECU n = 48 and
from both General Practitioner and MECU n = 5).
Treatment with adrenaline was mostly administered at
prehospital level, while glucocorticoids and antihista-
mines were more frequently administrated at the ED
and APW (Table 3).
Table 1 Symptoms listed by organ system according to WAO
anaphylaxis guidelines [1] comparing children/adolescents and
adults fulfilling the WAO/EAACI criteria for the diagnosis of
anaphylaxis (n = 180)
Symptoms Children/
adolescents
n = 23 (%)
Adults
n = 157 (%)
Skin, subcutaneous tissue and mucosa 23 (100) 146 (93)
Generalized itching 11 (48) 69 (47)
Generalized flushing/erythema 12 (52) 63 (43)
Generalized urticaria 7 (30) 53 (36)
Localized angioedema 7 (30) 55 (38)
Generalized angioedema 9 (39) 46 (32)
Respiratory tract 19 (83) 124 (79)
Sensation of throat tightness 7 (37) 78 (63)
Throat itching 7 (37) 27 (22)
Hoarseness 6 (32) 30 (24)
Wheezing/bronchospasm 11 (58) 48 (39)
Gastrointestinal tract 14 (61) 95 (61)
Dysphagia 5 (36) 47 (49)
Abdominal pain 9 (64) 30 (32)
Nausea 9 (64) 52 (55)
Vomiting 5 (36) 21 (22)
Diarrhea 3 (21) 13 (14)
Cardiovascular system 10 (43) 94 (60)
Tachycardiaa 7 (70) 71 (76)
Mild Hypotensionb 1 (10) 10 (11)
Severe hypotensionc 1 (10) 15 (16)
Urinary or fecal incontinence 1 (10) 7 (7)
Central Nervous System 11 (48) 72 (47)
Uneasiness 1 (9) 10 (14)
Altered mental status 7 (64) 42 (58)
Dizziness 0 (0) 12 (17)
Loss of consciousness 3 (27) 15 (21)
aHeart rate above or equal to 100 beats per minute
b Systolic blood pressure between 110 and 90 mmHg according to references [1, 12]
c Systolic blood pressure below 90 mmHg according to references [1, 12]
Boldface are marking the 5 different organ systems and for each organ system
the percentage distribution of symptoms are given
Table 2 Suspected elicitors of anaphylaxis in children/adolescents
and adults fulfilling the WAO/EAACI criteria for the diagnosis of
anaphylaxis (n = 180)
Suspected elicitors Children/adolescents
n = 23 (%)
Adults
n = 157 (%)
p value
Drugs 5 (22) 75 (48) 0.019
β-lactam antibiotic 1 (20) 30 (40)
ACE inhibitors 0 13 (17)
ASA/NSAIDs 3 (60) 9 (12)
Other drugsa 1 (20) 23 (31)
Food 14 (61) 26 (17) <0.001
Tree nuts 7 (50) 8 (31)
Peanuts 3 (21) 1 (4)
Fish/shellfish 0 3 (11)
Wheat 0 3 (11)
Other foodsb 4 (29) 11 (42)
Venom 1 (4) 37 (24) 0.035
Wasp 1 (100) 25 (67)
Bee 0 8 (22)
Other insectsc 0 4 (11)
Inhalation allergens 1 (4) 1 (1) 0.113
Unknown 2 (9) 18 (11) 0.693
a Iodinated Radio Contrast Media n = 5, Macrolides n = 1, Miconazole n = 1,
Acyclovir n = 1, Chloramphenicol n = 1, Metronidazole n = 2, Proton pump
inhibitor n = 1, Acrivastine n = 1, Chlorhexidine n = 1, Gabapentin n = 1,
Camphorated opium tincture n = 1, Xylometazoline n = 1, Lamotrigine n = 1,
topic Glucocorticoids n = 1, Calcium antagonist (felodipine) n = 1, Mesalazine n
= 1, Valerian root n = 1, Zopiclone n = 1, D- vitamin n = 1
b Milk n = 1, Carrot n = 1, Celery n = 1, Bugles chips n = 1, Oatmeal breakfast
cereal n = 1, Tomato n = 1, Fruit/fig bars (apple/raspberry) n = 1, Kiwi, parsley
root and parsnip n = 1, Poppy seed n = 1, Carry n = 1 Chicken, bread, pasta,
sour cream n = 1, Dressing (hydrolysate) n = 1, Red wine n = 1, Jensens Bøfhus®
sauce n = 1, Noodle soup n = 1
c Bumblebee, gadfly
Boldface are marking the different groups of elicitors and for each group the
percentage distribution of the specific elicitors are given
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In the group of patients with moderate to severe ana-
phylaxis (grade 3–5) only 25% (44/173) received treat-
ment with adrenaline according to guidelines (IM 93%,
IV 2%, IM + IV 5%) compared to the 84% (146/173) re-
ceiving glucocorticoids (p < 0.001) and the 91% (157/
173) receiving antihistamines (p < 0.001). Even in grade
5, only 58% (18/31) were treated with adrenaline (Fig. 3).
Adrenaline inhalations were administered in 9% (16/
173) of the patients with moderate to severe anaphylaxis,
of these 25% (4/16) were treated concomitantly with IM
adrenaline.
Based on symptoms in Sampson’s severity score adren-
aline should be administered immediately in 85% (147/
173) of the cases in grade 3–5; of those only 28% (41/
147) received adrenaline.
When comparing administered treatment in the group
of children and adults separately, the results did not
change.
Adrenaline auto injector was prescribed at the discharge
from the APW and ED in 40% of patients with food as the
suspected elicitor of anaphylaxis and in 60% of those with
venom as the suspected elicitor.
Discussion
This is one of the first prospective studies on the epi-
demiology of anaphylaxis in children and adults at a
large university hospital, where the patients are identified
not only based on diagnosis code but also on history,
symptoms and treatment and thereafter classified accord-
ing to international diagnosis criteria for anaphylaxis.
Table 3 Applied drugs among patients fulfilling the WAO/EAACI criteria for the diagnosis of anaphylaxis. Several answers are
possible (n = 180)
Treatment Pre-hospital Hospital Total cases
n = 180 (%)
Bystandera Physicianb Ambulance/MECU Emergency Department
Adrenaline 45 (25)
IM 10 4 23 7 44 (24)
IV 0 0 2 1 3 (2)
Glucocorticoids 150 (83)
IV 1 8 36 87 132 (73)
Oral 4 1 0 20 25 (14)
Antihistamines 164 (91)
IV 1 8 41 86 136 (76)
Oral 45 8 0 17 70 (39)
Adrenaline Inhalationc 0 0 9 7 16 (9)
a Patient/relatives, Personal in institution or at work or Friend
b General practitioner or doctor on call
c4/16 patients received also adrenaline IM
Boldface are marking the different treatments and the percentage distribution, including administration way, are given as percent of the total number of cases
Fig. 3 Treatment administrated in relation to the severity of the anaphylactic reaction in patients fulfilling WAO/EAACI criteria for the diagnosis of
anaphylaxis (n = 180)
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We found that the proportion of anaphylaxis in the
emergency setting is in line with previous epidemio-
logical studies in the ED [5, 6, 14] and the APW [7].
Moreover, the result suggests that in the group of adults,
anaphylaxis presentation in the ED is as frequent as ST-
elevation myocardial infarction [19].
In contrast, we found a higher IR of anaphylaxis (40.4
cases per 100,000 person years), compared to previous
studies in Europe, where the IR is reported to be 1.5–7.9
cases per 100,000 person year [3], and in Denmark
where the IR is reported to be increasing from 3.2 cases
per 100,000 person year late in the 80’s [20] to 6.46 cases
per 100,000 person year during 1995–2012 [21]. The
difference could be explained by different inclusion
criteria in the studies, and more specific the diagnosis
codes included. In both the retrospective and register
based studies of Soerensen et al [20] and Jeppesen et al
[21], only the cases having diagnosis codes related to
“anaphylactic shock” were included. In our study,
records from 42 allergy related diagnoses (ICD-10) were
reviewed, as well as all records with administered treat-
ment of adrenaline, antihistamines or glucocorticoids to
find as many cases as possible. Finally, the WAO/EAACI
criteria were used for our final diagnosis of anaphylaxis.
Similar differences were previously described by Bohlke
[22], who could identify six times more anaphylactic epi-
sodes among children and adolescents between 1991–
1997, when incorporating other allergy diagnosis besides
the diagnosis codes specific for anaphylaxis. In the same
way, a new retrospective and register based study of Lee
et al [4] including many anaphylaxis related diagnosis
(ICD-9), reported also a high IR of anaphylaxis in 42
cases per 100,000 person year, in line with our results.
Concerning the clinical characteristics of anaphylaxis,
our results are in line with previous studies: the high
proportion of moderate to severe anaphylaxis cases
regardless of the severity score applied [9, 13],skin and
respiratory symptoms as the most prevalent symptoms
[5, 14, 23] and cardiovascular symptoms being more
prevalent among adults compared to children [11]. It is
important to highlight that 7% of the adults in our study
population did not have symptoms from the skin and
mucosal tissue, whereas previous studies described the
absence of skin symptoms in up to 20% of anaphylaxis
cases [1, 10, 11]. The latter may represent a diagnostic
challenge, especially when it is not possible to collect an
appropriate history of symptoms or elicitors as it may
be the case with children, elderly or unconsciousness
patients.
Age related differences in the elicitors profile have also
been described in other studies in Europe and North
America [2, 3, 7, 9]. These differences could be explained
by the fact that adults are more exposed to drugs and in-
sect stings than children/adolescents. Furthermore, food
allergies are more common in children and the prevalence
decreases with increasing age [24, 25].
Finally, our results about treatment of anaphylaxis
substantiate those from others studies worldwide, where
glucocorticoids and antihistamines seems to be adminis-
tered almost as a routine, and adrenaline is administered
in a lower proportion [6, 9, 13, 14, 23]. This is in con-
trast to international guidelines [1, 12]. Adrenaline as
the first-line drug for anaphylaxis was administered in
only 25% of the 173 patients with moderate to severe
anaphylaxis in our study group. Whether these findings
reflect the assessment of the physician on charge or in-
sufficient treatment of the anaphylactic reaction or both
cannot be clarified. However, the low degree of adminis-
tration of adrenaline may be related to various factors.
Firstly, the fact that anaphylaxis is mostly a prehospital
condition with rapid onset, where the only possibilities
to get the treatment immediately is, that the patient is
equipped with an adrenaline auto injector (as was the
case for 10 of our patients) or that the patient get med-
ical help immediately (as 66 of our patients did, but only
27 were treated with adrenaline). This can probably
explain why adrenaline was mostly administered at pre-
hospital level in our study. Secondly, the improvement
or even disappearance of the symptoms may occur spon-
taneously in some cases or because the allergen in ques-
tion is removed (as may be the case in food induced
anaphylaxis after vomiting). Besides, in some cases pre-
existing cardiovascular conditions may have affected the
decision on whether to use epinephrine or not.
Adrenaline is recommended to treat anaphylaxis
due to its effect on α-1, β-1 and β-2 receptors [12]
and is the only drug effective for all symptoms in ana-
phylaxis including hypotension and the severe respiratory
symptoms [12]. The progression is fast, the course unpre-
dictable and delayed injection of adrenaline has been de-
scribed to be associated with fatal anaphylaxis [26, 27].
These facts support the importance of the prompt admin-
istration of adrenaline as well as the prescription of adren-
aline auto injectors at the discharge from the emergency
care settings and the reference of the patients to further
allergological investigation. Standardized educational in-
terventions including treatment algorithm and lectures on
recognition, grading and management of anaphylaxis
among personal at prehospital level and the staff at the
ED and APW, could improve the timely administration of
adrenaline.
A limitation of this study is that only patients who
were referred to the Allergy Center and gave consent to
participate in the study were included. Therefore, our
estimates are minimum figures as we cannot rule out
that some of the patients who declined participation, or
were excluded, could have had anaphylaxis. Further-
more, some contacts may have been missed since some
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patients living in OUH’s catchments area may have
attended other hospitals during the study period for ana-
phylaxis. Also, a potential source of error is the possibil-
ity of cases of fatal anaphylaxis at pre-hospital level not
being registered in the MECU or ED. Finally, the elicitor
profile is based on the patient history rather than on
diagnostic work-up.
The strengths of our study are the prospective inclusion
of the patients with a broad search on possible anaphylaxis
cases comprising the patient history, the administered
treatment and a wide list of possible IDC-10 diagnoses re-
lated to allergy and anaphylaxis. Besides this, our study is
based in a population that is representative for the Danish
general population. Furthermore, due to a carefully inter-
view at the Allergy Center and use of patients files from
the ED and APW, it was possible to classify all patients
according to established diagnostic criteria of anaphylaxis
and a severity score.
In this study focus was on the assessment and man-
agement of anaphylaxis at the admission to the emer-
gency care setting. In the future, this patient cohort will
be followed up after allergological diagnostic work-up to
verify the elicitors along with evaluation of co-morbidity
and co-factors in anaphylaxis.
Conclusion
Anaphylaxis occurred with a higher incidence compared
to previous studies but with the same elicitor profile.
Skin and respiratory symptoms were the most frequently
observed, but up to 7% of cases in adults occurred with-
out skin manifestations. The main elicitor of anaphylaxis
in children was food, while in adults drugs and venom
were the main elicitors. Adrenaline was administered
significant less than glucocorticoids and antihistamines.
Our findings reflect the need for standardized anaphyl-
axis criteria among physicians treating anaphylaxis as
well as the implementation of anaphylaxis guidelines regard-
ing diagnosis and treatment.
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